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Fatal intraoperative thrombosis in contemporary adult thoracic aortic
surgery requiring deep hypothermic circulatory arrest: Observations
from the literature, 1993–2006
John G. T. Augoustides, MD, FASE, Philadelphia, Pa
Fatal intravascular coagulation in the setting of thoracicaortic surgery with deep hypothermic circulatory arrest(DHCA) was highlighted in a case series (n  20) thatidentified exposure to aprotinin as a significant risk fac-
tor.1 The findings in this case series have since been attributed to
inadequate heparinization because it was only appreciated there-
after that aprotinin prolongs the celite-based activated clotting time
(ACT).2 However, even in the presence of adequate heparinization
by kaolin-based ACT or heparin concentration, case reports of
fatal thrombosis in thoracic aortic surgery with DHCA have per-
sisted (n  5, 1998–2006).2–5 The purpose of this brief commu-
nication is to review this case series as a platform from which
further research can be planned. The literature search was con-
ducted with PubMed (last entry: May 21, 2007) with the following
search terms: thrombosis and DHCA; aprotinin and thrombosis in
DHCA; aminocaproic acid and thrombosis in DHCA; and tranex-
amic acid and thrombosis in DHCA.
As a group, the published case reports of adult DHCA throm-
bosis can be summarized as follows2–5:
1. The 5 patients were all older than 60 years (2 men and 3
women).
2. All underwent thoracic aortic procedures with DHCA.
3. Factor V Leiden was identified in 2 of the 5 patients.4,5
4. All patients had antifibrinolytic therapy (3 with aprotinin
and 2 with aminocaproic acid).
5. Anticoagulation was titrated with heparin to maintain the
ACT at longer than 500 seconds, the heparin concentration
at greater than 2.7 U/mL, or both. The kaolin-based ACT
was always used in the presence of aprotinin.
6. Circulatory collapse caused by intravascular thrombosis
began in all cases within 60 minutes of separation from
cardiopulmonary bypass and protamine administration.
7. The circulatory collapse was life-threatening and resistant
to pharmacologic support. In all cases it necessitated return
to cardiopulmonary bypass.
8. The degree of thrombosis was massive, involving the heart
chambers, thoracic aorta, pulmonary arteries, and great veins.
In 4 of 5 patients, the disseminated thrombus was evident
intraoperatively. In the fifth patient autopsy revealed extensive
thrombosis within the small pulmonary arteries that was re-
sponsible for fatal intraoperative right ventricular failure.
9. The syndrome caused intraoperative death in all 5 patients.
Of course, this small case series has the usual inherent limita-
tions. There are many more questions than answers. However, the
following observations might serve to direct further investigation
of this lethal syndrome to improve its management:
1. A worldwide case registry would allow a greater case num-
ber for further in-depth analysis.
2. Hypercoagulable states, such as Factor V Leiden, might
have a role in the pathophysiology of this syndrome.
3. In the presence of an antifibrinolytic, standard-of-care anti-
coagulation with heparin for adult DHCA does not protect
all patients against serious intraoperative thrombotic com-
plications.
4. Aprotinin is not the only antifibrinolytic associated with this
syndrome. To date, no cases of this syndrome have been
reported in association with tranexamic acid.
5. When a case occurs, the following considerations might
improve clinical care:
a. Blood samples from the patient should be analyzed in
consultation with a hematologist to identify possible
mechanisms.
b. The index patient and family should be screened for
underlying hypercoagulable states.
c. Patient autopsy might be required to determine the
mechanism of death, especially if the thrombosis is not
evident intraoperatively.
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Despite the major advances in thoracic aortic surgery with
DHCA, there are still major clinical challenges, including this
thrombotic syndrome in the face of standard-of-care anticoagula-
tion. Further collaborative research should advance our under-
standing and management of this thrombotic syndrome in the
future.
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An innovative technique for the relief of right ventricular trabecular
cavity obliteration in endomyocardial fibrosis
Ana Olga Mocumbi, MD,a Daniel Sidi, MD, PhD,b Pascal Vouhe, MD, PhD,a and Magdi Yacoub, FRS,a London, United
Kingdom, Maputo, Mozambique, and Paris, France
Endomyocardial fibrosis (EMF) mainly affects personsfrom Africa, South America, and Asia.1 The pathogen-esis of this condition remains unknown. In advancedforms, EMF produces marked disability and carries a
poor prognosis. Although there is consensus about the potential
value of surgical intervention in symptomatic patients, there is still
debate regarding the exact timing and the surgical technique to be
used.2,3
EMF is characterized by endocardial fibrosis affecting the
inflow tract and the apex of 1 or both ventricles, commonly
involving the atrioventricular valves. The right ventricle is affected
in most cases.4 In severe forms, marked reduction of ventricular
volume is thought to be due to the presence of a plug of fibrous
tissue involving both the trabecular part and the apex.5
We here describe a new mechanism for apical obliteration of
the right ventricle in EMF. The concept was used to evolve and
apply a new surgical technique to increase ventricular volume,
improve contractile function by releasing the myocardium and
making use of viable myocardium in the obliterated area, and
correct the tricuspid regurgitation.
This technique was conceived after detailed echocardiographic
examination showed a layer of endocardial fibrosis forming an
artificial floor to the right ventricle and isolating the trabecular part
from the rest of the ventricular cavity (Figure 1, A).
After establishing cardiopulmonary bypass with moderate hy-
pothermia, cold blood antegrade cardioplegia was used for myo-
cardial protection. A wide longitudinal right atriotomy was per-
formed to expose the tricuspid valve, which was usually markedly
dilated, allowing wide access to the right ventricle. The distribu-
tion and extent of pathologic involvement of the tricuspid valve
apparatus and right ventricular cavity were carefully defined.
In patients with obliteration of the trabecular part of the right
ventricle described in this article, white glistering fibrous tissue 2
to 3 mm in thickness was found lining the inflow tract and
extended down into the cavity of the right ventricle to the level of
the junction of the inflow and trabecular parts. The fibrotic process
produced a relatively thin layer that formed an “artificial floor” to
the right ventricle, separating the inflow cavity from the obliterated
muscular trabecular part. The fibrotic process spared the tricuspid
leaflets and chordae.
Endocardial resection was started near the tricuspid annulus by
retracting the leaflets of the valve. If the latter was fused in some
areas, it was mobilized if at all possible. After the development of
a cleavage plane by means of sharp dissection, a combination of
sharp and blunt dissection was used to excise the thick, fibrous
endocardial lining. This process was continued into the ventricular
cavity, ensuring preservation and mobilization of the tricuspid
valve chordae and papillary muscles. The membrane covering the
entry into the trabecular part was removed (Figure 1, B), exposing
the fused muscular tissue underneath it. This was followed by
recreating a cavity inside the trabecular part by mainly separating
the fused trabeculae but, if necessary, also excising some muscular
tissue, taking care not to perforate the ventricular wall.
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